Trials involving CARv3-TEAM T cells targeting EGFRvIII, infused intraventricularly, and bivalent CARs targeting EGFR and IL13Rα2 via the intrathecal route have shown rapid and significant radiographic tumour regression, although some patients experienced early-onset neurotoxic complications that were managed with steroids and IL-1R antagonists [120]. Here, EGFR is linked to neoplasm.